Description
Molnulee (Molnupiravir) 200 mg
Molnulee is a brand name for molnupiravir, an oral antiviral medicine used for COVID-19 in certain adults. The product shown here is a 200 mg capsule presentation. Regulatory sources identify molnupiravir as an oral antiviral with activity against SARS-CoV-2, the virus that causes COVID-19.
Active Ingredient and Medicine Class
The verified active ingredient is molnupiravir. It is a nucleoside analogue antiviral and a prodrug of the active metabolite N-hydroxycytidine.
Established Medical Uses
Molnupiravir has been authorised in some settings for the treatment of mild-to-moderate COVID-19 in adults who are at high risk of progression to severe disease, including hospitalization or death, when other treatment options are not suitable or accessible. The exact authorised use can vary by country and regulatory status.
How It Works
Molnupiravir is converted in the body to an active form that is incorporated by the viral RNA polymerase during SARS-CoV-2 replication. This causes errors in the viral genetic code, making it harder for the virus to reproduce effectively. Human and mechanistic studies support this RNA mutagenesis mechanism.
Important Safety Information
Molnupiravir is not recommended during pregnancy because of concerns from animal reproduction data and the potential risk to the fetus. Regulatory information also advises caution regarding use in people with reproductive potential, reflecting the need to consider possible genetic and developmental risks.
Available regulatory fact sheets note that major drug interactions are not a prominent feature of molnupiravir compared with some other antivirals, but all medicines should still be reviewed for suitability in the individual patient.
Possible Side Effects
Reported adverse effects include diarrhea, nausea, and headache. Clinical reviews and meta-analyses have generally found no clear increase in serious adverse events compared with placebo, although safety monitoring remains important.
Scientific Evidence
Randomized trials in non-hospitalized adults with COVID-19 have evaluated molnupiravir for reducing clinical progression, with published analyses showing antiviral activity and a reduction in hospitalization or death in some high-risk populations. Later systematic reviews found benefits on viral clearance and little to no difference in serious adverse events overall, though results vary by study population and variant era.
Medical Information Notice
This summary is for educational purposes only and is based on sources available at the time of review. It does not replace the official patient leaflet, prescribing information, or individual assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration (FDA): Fact Sheet for Healthcare Providers: Emergency Use Authorization for LAGEVRIO (molnupiravir) capsules. View source
- DailyMed: LAGEVRIO (molnupiravir) capsule product information. View source
- Jayk Bernal et al.: Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. New England Journal of Medicine, 2021. PubMed
